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We planned a multicenter randomized phase III study to evaluate the efﬁcacy of appropriate
dose of bevacizumab (5 or 10 mg/kg) with FOLFIRI in patients with advanced/metastatic colo-
rectal cancer who have failed prior bevacizumab plus oxaliplatin-based therapy. The primary
endpoint is progression-free survival. The secondary endpoints are the toxicity, response
rate, time to treatment failure, overall survival, overall survival from the start of the ﬁrst-line
treatment and second progression-free survival (time duration from the initiation of the ﬁrst-
line treatment until progression after the protocol treatment). A total of 370 patients were con-
sidered to be appropriate for this trial.
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INTRODUCTION
Age-adjusted prevalence of colorectal cancer (CRC) is the
second largest percentage after that of gastric cancer in
males and breast cancer in females in Japan (1). According
to the CONCORD study, it is reported that Japanese men
attain the ﬁrst place and Japanese women attain sixth for a
5-year survival rate with CRC in the world (2). Japanese
patient’s clinical registered data from 1991 to 1994 by the
Japanese Society for Cancer of the Colon and Rectum is su-
perior to the same period’s data from Survival Epidemiology
and End Results and National Cancer Data Base for each of
Stage I, II, III CRC, at most 20%.
It is estimated that the number of CRC patients will be 480
396 in 2015 and 512 225 in 2020 (1). It is also expected that
the incidence of CRC will overtake that of breast cancer after
2010. Although CRC screening rates were improved, consid-
erably large number of patients had a locally advanced or
metastatic disease at the time of diagnosis. For patients with
metastatic CRC, recommended ﬁrst-line regimens by guide-
lines are FOLFOX or FOLFIRI (3,4) plus biological agents.
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cisco, CA), a recombinant, humanized monoclonal antibody
that binds to and neutralizes vascular endothelial growth
factor (VEGF) is one of the biological agents and was proved
to improve overall survival (OS) and progression-free survival
(PFS) in bevacizumab-naı ¨ve patients with metastatic CRC
when administered to ﬁrst- and second-line chemotherapy.
For patients with previously treated metastatic CRC, treat-
ment results of FOLFIRI or FOLFOX as a second-line
therapy were reported from the phase III study. PFS was 2.5
and 4.2 months, respectively (5). Treatment results of
FOLFIRI plus bevacizumab at 5 mg/kg and FOLFOX plus
bevacizumab at 5 mg/kg as a second-line treatment were
reported from the phase II study. PFS was 7.8 and 5.3
months, respectively (6). In addition, the treatment result of
FOLFOX4 plus bevacizumab at 10 mg/kg as a second-line
therapy was reported from a randomized phase III study. OS
as the primary objective was 12.9 months compared with
10.8 months of FOLFOX4 alone (HR, 0.66; P , 0.0011).
PFS was 7.3 months, which is also signiﬁcantly
improved compared with 4.7 months of FOLFOX4 alone
(HR, 0.61; P , 0.0001) (7). However, all of these treatments
were examined for previously bevacizumab-naı ¨ve patients.
A key element of continuous administration of bevacizu-
mab beyond progression is as shown below. In basic re-
search, regrowth of tumor vessels are often observed soon
after cessation of bevacizumab administration (8–10)a n d
VEGF expression is identiﬁed across the board from the
initial period of the tumor lifecycle (11). Several experimen-
tal studies have examined that the muMAb 4.6.1 antibody,
mouse monoclonal precursor of VEGF inhibitors in CRC
xenograft models prevents growth of tumor cells at metastat-
ic sites dose dependently (12). In addition, the BRiTE
study (13), one of the observational cohort studies in the
USA provides supportive clinical data about the foregoing.
Median OS were 12.6, 19.9 and 31.8 months in the no post-
progressive disease (PD) treatment, chemotherapy without
bevacizumab and chemotherapy with bevacizumab groups,
respectively.
After adjustment for other prognostic factors, bevacizumab
treatment beyond progression maintained a statistically
signiﬁcant effect on survival after PD, compared
with no post-PD bevacizumab (HR, 0.49; 95% CI, 0.41–0.58;
P, 0.001). In this study, the proportion of bevacizumab doses
administered as the second-line therapy were 90.7% (5 mg/kg),
3.6% (7.5 mg/kg) and 2.3% (10 mg/kg). These results from
the BRiTE study suggest that continuous VEGF inhibition
with bevacizumab beyond initial PD could play an important
role for prolonging survival of patients with metastatic CRC.
There are three major clinical questions to be solved
about second-line biological agents in metastatic colorectal
cancer. The ﬁrst clinical question about the continuation
of bevacizumab after exposure to bevacizumab treatment
will be revealed from the results of the on-going trial
‘AIO 0504’. The second clinical question about the drug
selection between bevacizumab and anti-epidermal growth
factor receptor antibodies with KRAS wild type after a
ﬁrst-line bevacizumab-containing regimen will also be
answered by the on-going trial ‘SPIRITT’.
On the other hand, the third clinical question about the
optimal doses of bevacizumab as second-line treatment fol-
lowed by a bevacizumab-containing regimen is still remains
unsolved. The veriﬁed data indicates the efﬁcacy of bevaci-
zumab at 5 mg/kg/weekly (¼10 mg/kg/biweekly) in the
second-line setting followed by bevacizumab-naı ¨vet r e a t -
ment (7). The recommended dose of bevacizumab is 5 mg/
kg/weekly (¼10 mg/kg/biweekly) in non-small cell lung
cancer, breast cancer, renal cell cancer and second-line colo-
rectal cancer (14–19), but 2.5 mg/kg/weekly (¼5 mg/kg/bi-
weekly) in the ﬁrst-line CRC treatment. The dose of
bevacizumab 2.5 mg/kg/weekly (¼5 mg/kg/biweekly) could
be lower than the recommended dose in the second-line
CRC treatment.
Thus, it is necessary for us to investigate the effectiveness
of high-dose bevacizumab for metastatic CRC.
Accordingly, we have conducted a randomized phase III
study of FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/
kg as second-line therapy in patients with metastatic CRC
who have failed ﬁrst-line bevacizumab plus oxaliplatin-based
therapy (EAGLE study).
The study protocol was approved by the institutional
review boards of each participating institution. The study
met the ethical guidelines for clinical studies of the Health,
Labor and Welfare Ministry in Japan, and was conducted in
compliance with the Declaration of Helsinki. All patients
provided written informed consent.
PROTOCOL DESIGN FOR EAGLE STUDY
OBJECTIVE
A multicenter randomized phase III study of adding bevaci-
zumab 5 or 10 mg/kg to FOLFIRI in advanced/metastatic
CRC who have failed prior bevacizumab plus oxaliplatin-
based ﬁrst-line therapy.
ENDPOINT
The primary endpoint is PFS. The secondary endpoints are
the toxicity, response rate, time to treatment failure, OS, OS
from the start of the ﬁrst-line treatment and second PFS
(time duration from the initiation of the ﬁrst-line treatment
until progression after the protocol treatment). The progres-
sion will be evaluated on the basis of response evaluation
criteria in solid tumors (RECIST) ver. 1.1.
ELIGIBILITY CRITERIA
INCLUSION CRITERIA
(i) PD after chemotherapy with bevacizumab plus
oxaliplatin-based therapy as the ﬁrst-line treatment
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difﬁcult to continue the ﬁrst-line therapy due to the
other reasons.
(ii) Oxaliplatin and bevacizumab were administered for
more than four times in the ﬁrst-line treatment.
(iii) Cytologically and/or histologically proven CRC.
(iv) Written informed consent.
(v) Aged 20 years old and above.
(vi) Eastern Cooperative Oncology Group performance
status (ECOG PS) 0 or 1.
(vii) Life expectancy estimated  3 months.
(viii) Sufﬁcient organ functions.
EXCLUSION CRITERIA
(i) Previous irinotecan treatment.
(ii) Administration of transfusion/hematopoietic factor or
antithrombotic drug within 14 days.
(iii) Serious renal dysfunction.
(iv) Serious drug hypersensitivity or a history of drug
allergy.
(v) Active concomitant malignancy.
(vi) Active infections.
(vii) Symptomatic or asymptomatic heart disease that is
being treated at the time of registration to the trial.
(viii) History of thrombosis, interstitial pneumonia, pul-
monary ﬁbrosis or high-grade pulmonary
emphysema.
(ix) Fresh hemorrhage from the digestive tube, intestinal
tube paralysis, intestinal obstruction and peptic ulcer.
(x) Pleural effusion, peritoneal ﬂuid and pericardial
ﬂuid.
(xi) Symptomatic brain metastasis.
(xii) History of mental disturbances or cerebrovascular
accident.
(xiii) High blood pressure and diabetes that cannot be
controlled.
(xiv) Uncontrolled diarrhea.
(xv) Serious non-healing wound and/or major surgical
procedure within 4 weeks prior to enrolling in this
trial.
(xvi) Traumatic fracture that has not been headed at the
time of enrollment.
(xvii) Bleeding tendency and anti-platelet therapy (includ-
ing aspirin and non-steroidal anti-inﬂammatory
drugs).
(xviii) Pregnant women, possibly pregnant women, wishing
to become pregnant and nursing mothers.
(xix) Needing treatment with atazanavir sulfate.
(xx) Paralyzed bowel.
REGISTRATION
Any medical institution that would like to participate could
contact a secretariat at Epidemiological and Clinical
Research Information Network (ECRIN) or publicly contact:
Hideyuki Mishima at the Department of Surgery, National
Hospital Organization Osaka National Hospital, Osaka,
Japan.
Registration forms are sent from the ECRIN to the
medical institution for registration.
Registered patients are allocated randomly into the
FOLFIRI þ 5 mg of bevacizumab arm (arm A) or the
FOLFIRI þ 10 mg of bevacizumab arm (arm B) at the data-
center. For randomization, a minimization method or
dynamic randomization is used with ﬁve balancing factors:
baseline ECOG PS, number of metastasis (2.,2  ), reason
for a change in therapy to second-line treatment (PD in ﬁrst-
line treatment/non-PD), early recurrence within 6 months
(during/after adjuvant treatment) and institutions.
TREATMENT METHODS
FOLFIRI plus bevacizumab consists of bevacizumab at
5 mg/kg (or 10 mg/kg) as a 30-min infusion and l-leucovorin
200 mg/m
2 as a 2-h infusion, and concurrently irinotecan
150 mg/m
2 as an over 90-min infusion, followed by bolus
ﬂuorouracil (5-FU) 400 mg/m
2 within 15 min and 46-h infu-
sion of 5-FU 2400 mg/m
2. Patients randomly assigned to
arm A receive FOLFIRI plus bevacizumab 5 mg/kg.
FOLFIRI plus bevacizumab 10 mg/kg is administered to
patients randomly assigned to arm B. These treatments are
repeated every 2 weeks until disease progression, unaccept-
able toxicity or patient choice.
FOLLOW-UP
Disease progression and occurrence of new diseases are
monitored by using abdominal radiography, abdominal com-
puted tomography (CT) or magnetic resonance imaging, and
thoracic CT, and by measuring levels of the tumor markers
CEA and CA19–9 at the baseline and every 8 weeks during
the treatment period (tumor marker levels are measured
every 4 weeks). Blood tests and symptom checks (collecting
adverse events) will be carried out throughout the treatment
period. In case of dyspnea, arterial blood gases will be tested
and chest X-ray test will be carried out. In case of arrhyth-
mia, a 12 lead electrocardiogram will be carried out. The
follow-up period is 1 year after the registration of the last
patient.
STUDY DESIGN AND STATISTICAL ANALYSIS
The primary objective of this trial is to evaluate whether
arm B (FOLFIRI plus 10 mg/kg of bevacizumab therapy)
signiﬁcantly improves PFS compared with arm A (FOLFIRI
plus 5 mg/kg of bevacizumab therapy). The null hypothesis,
if the PFS of both arms is equal, is tested by the stratiﬁed
log-rank test with the balancing variables (except for the
institutions) as the stratiﬁcation factor. If arm B showed a
statistically signiﬁcant prolonging effect on PFS compared
with the other arm, it is concluded that arm B is more
136 FOLFIRI plus bevacizumab as second-line treatmentbeneﬁcial therapy. The overall signiﬁcance level of the trial
is set as 5% for the two-sided test.
PFS curves are depicted by the Kaplan–Meier method.
Median PFS and the annual PFS rates are also estimated
using the Kaplan–Meier method with the two-sided 95%
conﬁdence interval using the Greenwood formula (20). The
stratiﬁed Cox proportional hazards model is used to assess
the hazard ratio with Wald-type 95% conﬁdence intervals
for the treatment effect between both arms.
Median PFS of arm A in this trial is assumed to be 5.0
months based on previous studies (6,7) and it is considered
as a clinically relevant prolongation if the median PFS of
arm B is 7.0 months (risk reduction 30%). At the start of
this trial, the planned sample size was 280 patients to detect
30% risk reduction with 80% power for a log-rank test com-
paring two survival curves with a two-sided signiﬁcance
level of 0.05, assuming an accrual time of 2 years and a
follow-up time of 1 year (21). This calculation was carried
out by employing nQuery Advisor 7.0 software (Statistical
Solutions, Saugus, MA, USA). On 8 April 2011, an inde-
pendent data monitoring committee of the EAGLE trial
recommended that the statistical power be amended from 80
to 90% with the consideration of the promising enrollment
of patients. As a result, 358 patients (330 events) will be
needed to detect 90% power under the same assumption.
Taking some dropouts into account, the sample size to be
accrued was set at 370 patients in total.
THE EAGLE TRIAL GROUP
Principal investigator: H. Mishima (Osaka National
Hospital, Osaka, Japan).
Promotion committee chairman:Y .M a e h a r a( G r a d u a t e
School of Medical Science, Kyushu University, Fukuoka,
Japan).
Data and safety monitoring board: I. Hyodo (University of
Tsukuba Graduate School of Comprehensive Human
Sciences, Ibaraki, Japan), K. Muro (Aichi Cancer Center
Hospital, Aichi, Japan) and T. Yoshino (National Cancer
Center Hospital East, Chiba, Japan).
Data center: J. Sakamoto (Nagoya University Graduate
School of Medicine, Aichi, Japan) and C. Abe (ECRIN,
Kyoto, Japan).
Statistical advisor: K. Oba (Hokkaido University, Hokkaido,
Japan).
Participating institutions: Approximately 150 Japanese insti-
tutions and hospitals are participating in this trial.
Acknowledgement
This study is and will be supported in part by a non-proﬁt
organization ECRIN.
Funding
Research grant from a non-proﬁt organization ECRIN.
Conﬂict of interest statement
None declared.
References
1. Center for Cancer Control and Information Services, National
Cancer Center, Japan. Statistics. http://ganjoho.jp/public/statistics/index.
html (in Japanese).
2. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R,
Capocaccia R, et al. Cancer survival in ﬁve continents: a worldwide
population-based study (CONCORD). Lancet Oncol 2008;9:730–56.
3. National Comprehensive Cancer Network. NCCN Clinical Practice
Guidelines in Oncology. http://www.nccn.org/professionals/
physician_gls/f_guidelines.asp.
4. Colorectal cancer treatment guideline for doctor ver, 2009. http://www.
jsccr.jp/guideline.html.
5. Tournigand C, Andre T, Achille E, Flesh M, Mery-Migmard D,
Quinaux E, et al. FOLFIRI followed by FOLFOX6 or the reverse
sequence in advanced colorectal cancer: a randomized GERCOR study.
J Clin Oncol 2004;22:229–37.
6. Senellart H, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R,
et al. Bevacizumab combined with chemotherapy in the second-line
treatment of metastatic colorectal cancer (mCRC): 12-month results of a
phase II study (bevacolor). In: 2008 Gastrointestinal Cancers
Symposium (abstract 493).
7. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP,
Alberts SR, et al. Bevacizumab in combination with oxaliplatin,
ﬂuorouracil, and leucovorin (FOLFOX4) for previously treated
metastatic colorectal cancer: results from the Eastern Cooperative
Oncology Group Study E3200. J Clin Oncol 2007;25:1539–44.
8. Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE.
Angiogenesis inhibition by vascular endothelial growth factor
receptor-2 blockade reduces stromal matrix metalloproteinase
expression, normalizes stromal tissue, and reverts epithelial tumor
phenotype in surface heterotransplants. Cancer Res 2005;65:1294–305.
9. Kamba T, Tam B, Hashizume H, Haskell A, Sennino B, Mancuso MR,
et al. VEGF-dependent plasticity of fenestrated capillaries in the normal
adult microvasculature. Am J Physiol Heart Circ Physiol
2006;290:H560–76.
10. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al.
Inhibition of vascular endothelial growth factor (VEGF) signaling in
cancer causes loss of endothelial fenestrations, regression of tumor
vessels, and appearance of basement membrane ghosts. Am J Pathol
2004;165:35–52.
11. Folkman J. Angiogenesis: an organizing principle for drug discovery?
Nat Rev Drug Discov 2007;6:273–86.
12. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by
vascular endothelial growth factor of human colon cancer tumor genesis
in a mouse model of experimental liver metastasis. JC l i nI n v e s t
1995;95:1789–97.
13. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E,
et al. Bevacizumab beyond ﬁrst progression is associated with prolonged
overall survival in metastatic colorectal cancer: results from a large
observational cohort study (BRiTE). J Clin Oncol 2008;26:5326–34.
14. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ,
Jablons DM, et al. Randomized phase II trial comparing bevacizumab
plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in
previously untreated locally advanced or metastatic non–small-cell lung
cancer. J Clin Oncol 2004;22:2184–91.
15. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al.
Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell
lung cancer. N Engl J Med 2006;355:2542–50.
16. Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V,
Hirsh V, et al. BO17704 (AVAiL): a phase III randomized study of ﬁrst
line bevacizumab combined with cisplatin/gemcitabine (CG) in patients
Jpn J Clin Oncol 2012;42(2) 137(PTS) with advanced or recurrent non-squamous, non-small cell lung
cancer (NSCLC). Ann Oncol 2008;19 (late-breaking abstract 1).
17. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ,
Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular
endothelial growth factor antibody, for metastatic renal cancer. N Engl
J Med 2003;349:427–34.
18. Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, et al. A
randomized, double-blind study of bevacizumab in combination with
docetaxel as ﬁrst-line treatment of patients with HER2-negative locally
recurrent or metastatic breast cancer: efﬁcacy and safety: AVADO.
J Clin Oncol 2008;26 (meeting abstracts): LBA1011.
19. Horita Y, Hirashima Y, Yamada Y, Kato K, Nakamoto A,
Nishitani H, et al. Effects of bevacizumab on plasma concentration
of irinotecan and its metabolites in advanced colorectal cancer
patients receiving FOLFIRI with bevacizumab as second-line
chemotherapy. 2009 Gastrointestinal Cancers Symposium (abstract
380).
20. Greenwood M. The Natural Duration of Cancer. Reports on Public
Health and Medical Subjects No. 33. London: Her Majesty’s Stationery
Ofﬁce, 1926;1–26.
21. Lakatos E, Lan KK. A comparison of sample size methods for the
logrank statistics. Stat Med 1992;11:179–91.
138 FOLFIRI plus bevacizumab as second-line treatment